Open-Label, Randomized Study to Assess Safety and Efficacy of Slow and Accelerated Switching to Xanomeline/Trospium From Standard of Care Atypical Antipsychotics in Participants With Schizophrenia

Welcome back to another Psychiatric Times Insights series. In this episode titled, "The Switch Study: Why a New Mechanism Demands a New Approach," David Walling, PhD, address the unmet clinical needs in schizophrenia treatment that motivated the development of the study evaluating the transition from atypical antipsychotics to Cobenfy?